Similar articles for PMID: 22783792

Year	Number of Results
1990	1
1993	2
1996	1
1997	2
1998	1
1999	2
2000	3
2001	10
2002	2
2003	4
2004	7
2005	8
2006	2
2007	6
2008	6
2009	2
2010	6
2011	5
2012	6
2013	5
2014	4
2015	5
2016	3
2017	1
2018	2
2019	4
2020	3
2022	1
2024	0

1

The current system for prescribing antiretroviral therapy puts HIV-infected patients at risk of serious drug-drug interactions: is now the time for a paradigm shift in HIV care delivery?

Whitlock GG, Patel A, Edwards SG, Benn PD, Miller RF. Whitlock GG, et al. Clin Med (Lond). 2012 Jun;12(3):300-1. doi: 10.7861/clinmedicine.12-3-300. Clin Med (Lond). 2012. PMID: 22783792 Free PMC article. No abstract available.

2

Lipid lowering therapy in patients with HIV infection.

Wierzbicki AS, Reynolds TM, Crook MA, Tatler J, Peters BS. Wierzbicki AS, et al. Lancet. 1998 Nov 28;352(9142):1782. doi: 10.1016/S0140-6736(05)79858-5. Lancet. 1998. PMID: 9848376 No abstract available.

3

Epilepsy: Issues with antiepileptic drug use in HIV-infected patients.

Brew BJ, Thompson J. Brew BJ, et al. Nat Rev Neurol. 2012 Mar 13;8(4):187-8. doi: 10.1038/nrneurol.2012.36. Nat Rev Neurol. 2012. PMID: 22410581 No abstract available.

4

Systemic bioavailability of fluticasone proprionate.

Lipworth BJ. Lipworth BJ. Br J Clin Pharmacol. 2001 Oct;52(4):457-60. doi: 10.1046/j.0306-5251.2001.01456.x-i3. Br J Clin Pharmacol. 2001. PMID: 11678793 Free PMC article. No abstract available.

5

Oral availability of fluticasone propionate.

Andersson P, Brattsand R, Dahlström K, Edsbäcker S. Andersson P, et al. Br J Clin Pharmacol. 1993 Aug;36(2):135-6. doi: 10.1111/j.1365-2125.1993.tb04211.x. Br J Clin Pharmacol. 1993. PMID: 8398584 Free PMC article. No abstract available.

6

[Serious adverse events derived from the drug interactions of antiretroviral therapy].

Morales Conejo M, Moreno Cuerda VJ, Abellán Martínez J, Rubio R. Morales Conejo M, et al. Rev Clin Esp. 2008 Dec;208(11):557-60. doi: 10.1016/s0014-2565(08)76033-8. Rev Clin Esp. 2008. PMID: 19121266 Spanish.

7

The oral systemic availability of fluticasone propionate in man--preliminary data.

Bye A. Bye A. Br J Clin Pharmacol. 1993 Aug;36(2):136-7. doi: 10.1111/j.1365-2125.1993.tb04212.x. Br J Clin Pharmacol. 1993. PMID: 8398585 Free PMC article. No abstract available.

8

Absorption of high-dose inhaled corticosteroids.

Brutsche-Carlen M, Carlen-Brutsche I, Woodcock A. Brutsche-Carlen M, et al. Chest. 2000 May;117(5):1526. doi: 10.1378/chest.117.5.1526. Chest. 2000. PMID: 10807856 No abstract available.

9

Re: Dose proportionality of fluticosone proportionate hydrofluoroalkane pressurized metered dose inhalers (pMDIS) and comparability with chlorofluorocarbon pMDIS.

Lipworth BJ. Lipworth BJ. Respir Med. 2001 Feb;95(2):160-3. doi: 10.1053/rmed.2000.0973. Respir Med. 2001. PMID: 11217914 Free article. No abstract available.

10

Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen.

Clevenbergh P, Corcostegui M, Gérard D, Hieronimus S, Mondain V, Chichmanian RM, Sadoul JL, Dellamonica P. Clevenbergh P, et al. J Infect. 2002 Apr;44(3):194-5. doi: 10.1053/jinf.2001.0928. J Infect. 2002. PMID: 12099750

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

97 results

Results by year